Aladar Szalay Sells 8,064 Shares of Genelux Co. (NASDAQ:GNLX) Stock

Genelux Co. (NASDAQ:GNLX) major shareholder Aladar Szalay sold 8,064 shares of the company’s stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $3.50, for a total value of $28,224.00. Following the sale, the insider now owns 1,255,730 shares of the company’s stock, valued at $4,395,055. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Aladar Szalay also recently made the following trade(s):

• On Monday, April 22nd, Aladar Szalay sold 14,331 shares of Genelux stock. The stock was sold at an average price of $3.53, for a total value of $50,588.43.
• On Tuesday, April 16th, Aladar Szalay sold 48,683 shares of Genelux stock. The shares were sold at an average price of $3.53, for a total value of $171,850.99.

Genelux Stock Down 0.9 %

Shares of Genelux stock traded down $0.03 on Wednesday, reaching $3.45. 137,205 shares of the company were exchanged, compared to its average volume of 125,442. The company’s 50-day moving average is $5.95 and its two-hundred day moving average is $11.00. Genelux Co. has a 1-year low of $3.26 and a 1-year high of $40.98.

Genelux (NASDAQ:GNLX) last announced its quarterly earnings results on Friday, March 29th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.04). Equities research analysts forecast that Genelux Co. will post -0.81 earnings per share for the current year.

Analysts Set New Price Targets

GNLX has been the subject of a number of analyst reports. HC Wainwright reduced their price target on Genelux from $35.00 to $32.00 and set a “buy” rating for the company in a report on Tuesday, April 2nd. Benchmark reaffirmed a “speculative buy” rating and set a $30.00 target price on shares of Genelux in a report on Wednesday, April 3rd.

Institutional Trading of Genelux

Several large investors have recently added to or reduced their stakes in the business. Amalgamated Bank increased its position in Genelux by 250.8% in the 3rd quarter. Amalgamated Bank now owns 1,077 shares of the company’s stock valued at $26,000 after acquiring an additional 770 shares during the period. New York State Common Retirement Fund increased its position in Genelux by 17.6% in the 4th quarter. New York State Common Retirement Fund now owns 6,461 shares of the company’s stock valued at $91,000 after acquiring an additional 966 shares during the period. Exchange Traded Concepts LLC increased its position in Genelux by 34.0% in the 4th quarter. Exchange Traded Concepts LLC now owns 6,201 shares of the company’s stock valued at $87,000 after acquiring an additional 1,573 shares during the period. Falcon Wealth Planning increased its position in Genelux by 20.0% in the 4th quarter. Falcon Wealth Planning now owns 12,000 shares of the company’s stock valued at $168,000 after acquiring an additional 2,000 shares during the period. Finally, Tower Research Capital LLC TRC increased its position in Genelux by 216.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 2,956 shares of the company’s stock valued at $41,000 after acquiring an additional 2,021 shares during the period. 37.33% of the stock is currently owned by institutional investors and hedge funds.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.